Seladelpar Could 'Raise the Bar' in PBC Treatment
The investigational agent significantly improved liver biomarkers of disease activity and symptoms of pruritus in adults with PBC enrolled in a phase 3 trial.
Source: medscape.com
📰 Par Agonists News
Par Agonists News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Par Agonists. Real-time updates on events, politics, business and more.
Promising Phase 2 Results for Novel Oral Alzheimer's Drug
An investigational dual PPAR agonist modifies Alzheimers pathology and shows cognitive benefit in adults with mild-to-moderate disease and high plasma pTau-217 ratio, early data show.
Rebecca Edelmayer John Didsbury Fd Therapeutics Inc Alzheimer Association Clinical Trials Mini Mental State Examination
Source: medscape.com
Novel Drug Lanifibranor Promising for NASH
Lanifibranor, a first-in-class pan-PPAR agonist, hits the primary and key secondary end points in a phase 2b trial of patients with noncirrhotic, highly active nonalcoholic steatohepatitis.
Source: medscape.com